Unlock stock picks and a broker-level newsfeed that powers Wall Street.

Milan - Delayed Quote EUR

JOHNSON & JOHNSON (1JNJ.MI)

Compare
138.92
+2.44
+(1.79%)
At close: April 17 at 5:27:40 PM GMT+2
Loading Chart for 1JNJ.MI
  • Previous Close 136.48
  • Open 135.12
  • Bid 138.62 x --
  • Ask 139.20 x --
  • Day's Range 135.06 - 139.14
  • 52 Week Range 128.30 - 162.26
  • Volume 113
  • Avg. Volume 167
  • Market Cap (intraday) 334.776B
  • Beta (5Y Monthly) 0.48
  • PE Ratio (TTM) 17.61
  • EPS (TTM) 7.89
  • Earnings Date Jul 16, 2025
  • Forward Dividend & Yield 4.58 (3.30%)
  • Ex-Dividend Date May 27, 2025
  • 1y Target Est --

Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of various products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. The MedTech segment provides electrophysiology products to treat heart rhythm disorders; the heart recovery portfolio, which includes technologies to treat severe coronary artery disease requiring high-risk PCI or AMI cardiogenic shock; circulatory restoration products for the treatment of calcified coronary artery and peripheral artery diseases; and neurovascular care that treats hemorrhagic and ischemic stroke. This segment offers an orthopaedics portfolio that includes products and enabling technologies that support hips, knees, trauma, spine, sports, and other; surgery portfolios comprising advanced and general surgery technologies, as well as solutions for breast aesthetics and reconstruction; contact lenses under the ACUVUE brand; and TECNIS intraocular lenses for cataract surgery. It distributes its products to wholesalers, hospitals, and retailers, as well as physicians, nurses, hospitals, eye care professionals, and clinics. The company was founded in 1886 and is based in New Brunswick, New Jersey.

www.jnj.com

138,100

Full Time Employees

December 29

Fiscal Year Ends

Recent News: 1JNJ.MI

View More

Performance Overview: 1JNJ.MI

Trailing total returns as of 4/17/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

1JNJ.MI
1.29%
S&P 500 (^GSPC)
10.18%

1-Year Return

1JNJ.MI
6.34%
S&P 500 (^GSPC)
5.19%

3-Year Return

1JNJ.MI
1.03%
S&P 500 (^GSPC)
20.26%

5-Year Return

1JNJ.MI
1.03%
S&P 500 (^GSPC)
83.77%

Compare To: 1JNJ.MI

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: 1JNJ.MI

View More

Valuation Measures

Annual
As of 4/17/2025
  • Market Cap

    333.01B

  • Enterprise Value

    343.64B

  • Trailing P/E

    17.61

  • Forward P/E

    15.04

  • PEG Ratio (5yr expected)

    1.08

  • Price/Sales (ttm)

    4.30

  • Price/Book (mrq)

    5.34

  • Enterprise Value/Revenue

    4.38

  • Enterprise Value/EBITDA

    19.81

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    24.42%

  • Return on Assets (ttm)

    --

  • Return on Equity (ttm)

    --

  • Revenue (ttm)

    89.33B

  • Net Income Avi to Common (ttm)

    21.81B

  • Diluted EPS (ttm)

    7.89

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    24.52B

  • Total Debt/Equity (mrq)

    52.92%

  • Levered Free Cash Flow (ttm)

    --

Research Analysis: 1JNJ.MI

View More

Company Insights: 1JNJ.MI

Research Reports: 1JNJ.MI

View More

People Also Watch